Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma-an effective combination with unexpected toxicity

S. Aamdal, T. Bohman, B. Gerard, M. D'Incalci

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Resistance to alkylating agents is partly due to the presence of the DNA repair enzyme, termed O6 alkyltransferase (O6AT). Preclinical evidence of the transient restoration of sensitivity of cells resistant to nitrosoureas by pretreatment with a methylating agent, whose role is to deplete cells of O6AT activity and clinical evidence of such a depletion in patients lymphocytes, led us to test the sequential administration of dacarbazine 3 h prior to fotemustine, a chloroethylnitrosourea derivative. 24 patients with measurable advanced melanoma entered the trial and are evaluable. Toxicity was mainly haematological with early neutropenia and/or thrombocytopenia. Clinical activity (33%) was impressive especially on lung metastases with high complete response rate for that site (7/14). Unfortunately, the occurrence of a rapidly fatal pulmonary toxicity precludes further use of the regimen before a plausible explanation for this unexpected toxicity is obtained. Indeed, similar cases have been reported in other trials using the sequential schedule while no lung toxicity was reported in single agent or alternated administrations. Preclinical studies are ongoing to test the hypothesis of a glutathione depletion and the possibility of a rescue treatment.

Original languageEnglish
Pages (from-to)447-450
Number of pages4
JournalEuropean Journal of Cancer
Volume28
Issue number2-3
DOIs
Publication statusPublished - 1992

Fingerprint

fotemustine
Dacarbazine
Alkyl and Aryl Transferases
Melanoma
Lung
DNA Repair Enzymes
Alkylating Agents
Neutropenia
Thrombocytopenia
Glutathione
Appointments and Schedules
Lymphocytes
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{89726062f07045498b170463c4e6cca1,
title = "Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma-an effective combination with unexpected toxicity",
abstract = "Resistance to alkylating agents is partly due to the presence of the DNA repair enzyme, termed O6 alkyltransferase (O6AT). Preclinical evidence of the transient restoration of sensitivity of cells resistant to nitrosoureas by pretreatment with a methylating agent, whose role is to deplete cells of O6AT activity and clinical evidence of such a depletion in patients lymphocytes, led us to test the sequential administration of dacarbazine 3 h prior to fotemustine, a chloroethylnitrosourea derivative. 24 patients with measurable advanced melanoma entered the trial and are evaluable. Toxicity was mainly haematological with early neutropenia and/or thrombocytopenia. Clinical activity (33{\%}) was impressive especially on lung metastases with high complete response rate for that site (7/14). Unfortunately, the occurrence of a rapidly fatal pulmonary toxicity precludes further use of the regimen before a plausible explanation for this unexpected toxicity is obtained. Indeed, similar cases have been reported in other trials using the sequential schedule while no lung toxicity was reported in single agent or alternated administrations. Preclinical studies are ongoing to test the hypothesis of a glutathione depletion and the possibility of a rescue treatment.",
author = "S. Aamdal and T. Bohman and B. Gerard and M. D'Incalci",
year = "1992",
doi = "10.1016/S0959-8049(05)80074-7",
language = "English",
volume = "28",
pages = "447--450",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "2-3",

}

TY - JOUR

T1 - Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma-an effective combination with unexpected toxicity

AU - Aamdal, S.

AU - Bohman, T.

AU - Gerard, B.

AU - D'Incalci, M.

PY - 1992

Y1 - 1992

N2 - Resistance to alkylating agents is partly due to the presence of the DNA repair enzyme, termed O6 alkyltransferase (O6AT). Preclinical evidence of the transient restoration of sensitivity of cells resistant to nitrosoureas by pretreatment with a methylating agent, whose role is to deplete cells of O6AT activity and clinical evidence of such a depletion in patients lymphocytes, led us to test the sequential administration of dacarbazine 3 h prior to fotemustine, a chloroethylnitrosourea derivative. 24 patients with measurable advanced melanoma entered the trial and are evaluable. Toxicity was mainly haematological with early neutropenia and/or thrombocytopenia. Clinical activity (33%) was impressive especially on lung metastases with high complete response rate for that site (7/14). Unfortunately, the occurrence of a rapidly fatal pulmonary toxicity precludes further use of the regimen before a plausible explanation for this unexpected toxicity is obtained. Indeed, similar cases have been reported in other trials using the sequential schedule while no lung toxicity was reported in single agent or alternated administrations. Preclinical studies are ongoing to test the hypothesis of a glutathione depletion and the possibility of a rescue treatment.

AB - Resistance to alkylating agents is partly due to the presence of the DNA repair enzyme, termed O6 alkyltransferase (O6AT). Preclinical evidence of the transient restoration of sensitivity of cells resistant to nitrosoureas by pretreatment with a methylating agent, whose role is to deplete cells of O6AT activity and clinical evidence of such a depletion in patients lymphocytes, led us to test the sequential administration of dacarbazine 3 h prior to fotemustine, a chloroethylnitrosourea derivative. 24 patients with measurable advanced melanoma entered the trial and are evaluable. Toxicity was mainly haematological with early neutropenia and/or thrombocytopenia. Clinical activity (33%) was impressive especially on lung metastases with high complete response rate for that site (7/14). Unfortunately, the occurrence of a rapidly fatal pulmonary toxicity precludes further use of the regimen before a plausible explanation for this unexpected toxicity is obtained. Indeed, similar cases have been reported in other trials using the sequential schedule while no lung toxicity was reported in single agent or alternated administrations. Preclinical studies are ongoing to test the hypothesis of a glutathione depletion and the possibility of a rescue treatment.

UR - http://www.scopus.com/inward/record.url?scp=0026586976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026586976&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(05)80074-7

DO - 10.1016/S0959-8049(05)80074-7

M3 - Article

C2 - 1591062

AN - SCOPUS:0026586976

VL - 28

SP - 447

EP - 450

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 2-3

ER -